Bromocriptine manufacturers and suppliers in india

Bromocriptine

Properties

Melting point:: 215-218° (dec)

alpha: D20 -195° (c = 1 in methylene chloride)

Boiling point:: 891.3±65.0 °C(Predicted)

Density: 1.2734 (rough estimate)

refractive index: 1.6400 (estimate)

pka: pKa 4.90±0.05(80% MCS t = RT) (Uncertain)

Water Solubility: 2.07mg/L(temperature not stated)

Safety Information

Symbol(GHS): GHS07,GHS08

Signal word: Warning

Hazard statements: H361-H362-H302

Precautionary statements: P201-P202-P281-P308+P313-P405-P501-P264-P270-P301+P312-P330-P501-P201-P260-P263-P264-P270-P308+P313

Toxicity: An ergot alkaloid derivative that exhibits potent dopamine agonist properties, particularly at D2 dopamine receptors. Bromocriptine, like dopamine, inhibits prolactin release from the pituitary and so is used in endocrine disorders, such as hyperprolactinemia. It is also used in the treatment of Parkinson’s disease. A large “first-pass” effect is seen with bromocriptine, and peak concentrations occur about 1.5-3 h after ingestion, with a half-life of about 3 h. Nausea, vomiting, and orthostatic hypotension are among the acute adverse effects. Long-term use has been associated with dyskinesias, constipation, psychoses, digital spasm, and erythromelalgia. The LD50 in rabbits exceeds 1 g/kg, p.o., and 12 mg/kg, i.v.

Use

Bromocriptine, a semisynthetic ergot alkaloid derivative and prolactin inhibitor was introduced into medicine in 1976. It is used in the prevention of lactation, but because of the risk of rebound effect and since only 10% of women benefit therapeutically from such intervention, the United States Food and Drug Administration has requested manufacturers to no longer indicate preparations containing bromocriptine for this purpose. The World Health Organization is not aware of similar action having been taken elsewhere.